Dyslipidemia acts as a close link between cardiovascular risk and renal progression in nephrotic children

1. Hu P, Lu L, Hu B, Du PF. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome. Scand J Clin Lab Invest. 2009; 69:680-6.10.3109/0036551090298075119468931Open DOISearch in Google Scholar

2. Marsh JB. Lipoprotein metabolism in experimental nephrosis. Proc Soc Exp Biol Med. 1996; 213:178-86.10.3181/00379727-213-440488931662Search in Google Scholar

3. Joven J, Villabona C, Vilella E, Masana L, Albert R, Vall s M. Abnormalities of lipoprotein metabolism in patients with the nephritic syndrome. N Engl J Med. 1990; 323:579-84.10.1056/NEJM1990083032309052381443Search in Google Scholar

4. al-Shurbaji A, Humble E, Rudling M, Lindenthal B, Berglund L. Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids. 1998; 33: 165-9.10.1007/s11745-998-0192-z9507238Open DOISearch in Google Scholar

5. Zhou Y, Zhang X, Chen L, Wu J, Dang H, Wei M, et al. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2008; 295:F662-71.10.1152/ajprenal.00046.2008253686818614621Search in Google Scholar

6. Liang K, Vaziri ND. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 1997; 51:1933-7.10.1038/ki.1997.2639186885Open DOISearch in Google Scholar

7. Vaziri ND, Liang KH. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int. 1996; 50:887-93.10.1038/ki.1996.3888872963Open DOISearch in Google Scholar

8. Lechleitner M. Dyslipidaemia and renal diseasepathophysiology and lipid lowering therapy in patients with impaired renal function. J Clin Basic Cardiol. 2000; 3:3-6.Search in Google Scholar

9. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006; 290:F262-72.10.1152/ajprenal.00099.200516403839Search in Google Scholar

10. Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol. 2004; 19:744-8.10.1007/s00467-004-1460-x15085419Open DOISearch in Google Scholar

11. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in serum, without use of the use of preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.10.1093/clinchem/18.6.499Search in Google Scholar

12. Grubb A, Nyman U, Bjork J, Lindström V, Rippe B, Sterner G, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equaions for children. Clin Chem. 2005; 51:1420-31.10.1373/clinchem.2005.05155715961546Open DOISearch in Google Scholar

13. Marsik C, Endler G, Gulesserian T, Wagner OF, Sunder- Plassmann G. Classification of chronic kidney disease by estimated glomerular filtration rate. Eur J Clin Invest. 2008; 38:253-9.10.1111/j.1365-2362.2008.01934.x18339005Open DOISearch in Google Scholar

14. Hu P, Qin YH, Jing CX, Lei FY, Chen P, Li MF. Association of polymorphisms at restriction enzyme recognition sites of apolipoprotein B and E gene with dyslipidemia in children undergoing primary nephrotic syndrome. Mol Biol Rep. 2009; 36:1015-21.10.1007/s11033-008-9275-718512131Open DOISearch in Google Scholar

15. Anochie I, Eke F, Okpere A. Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc. 2006; 98:1977-81.Search in Google Scholar

16. Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore. 2005; 34:31-5.Search in Google Scholar

17. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989; 13:I80-93.10.1161/01.HYP.13.5_Suppl.I802490833Open DOISearch in Google Scholar

18. Wheeler DC. Lipids-what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant. 1995; 10:14-6.Search in Google Scholar

19. Li J, Yu L, Li N, Wang H. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats. Chin Med J (Engl). 2000; 113: 310-4.Search in Google Scholar

20. Hu P, Qin YH, Lu L, Hu B, Jing CX, Lei FY, et al. Genetic variation of apolipoprotein E does not contribute to the lipid abnormalities secondary to childhood minimal change nephrotic syndrome. Int Urol Nephrol. 2010; 42:453-60.10.1007/s11255-009-9531-319241136Open DOISearch in Google Scholar

21. De Sain-Van Der Velden MG, Reijngoud DJ, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol. 1998; 9: 1474-81.10.1681/ASN.V9814749697670Search in Google Scholar

22. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int. 1991; 40: 129-38.10.1038/ki.1991.1901921148Open DOISearch in Google Scholar

23. Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int. 2003; 64: 1780-6.10.1046/j.1523-1755.2003.00281.x14531811Search in Google Scholar

24. Vaziri ND, Kim CH, Phan D, Kim S, Liang K. Upregulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int. 2004; 66:262-7.10.1111/j.1523-1755.2004.00724.x15200432Open DOISearch in Google Scholar

25. Vaziri ND, Liang K, Parks JS. Acquired lecithincholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol. 2001; 280: F823-8.10.1152/ajprenal.2001.280.5.F82311292624Search in Google Scholar

26. Liang K, Vaziri ND. Down-regulation of hepatic highdensity lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int. 1999; 56:621-6.10.1046/j.1523-1755.1999.00585.x10432401Open DOISearch in Google Scholar

27. Majumdar A, Wheeler DC. Lipid abnormalities in renal disease. J R Soc Med. 2000; 93:178-82.10.1177/014107680009300406129797310844882Search in Google Scholar

28. Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res. 2010; 33:100-10.10.1159/00030271220357496Open DOISearch in Google Scholar

29. Liu BC, Wu XC, Wang YL, Wang B, Gao J, Zhang QJ, et al. Investigation of the prevalence of CKD in 13, 383 Chinese hospitalised adult patients. Clin Chim Acta. 2008; 387:128-32.10.1016/j.cca.2007.09.02018028892Search in Google Scholar

30. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009; 4:1832-43.10.2215/CJN.0164030919820136Open DOISearch in Google Scholar

31. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006; 10:1-7.10.1111/j.1542-4758.2006.01168.x16441821Open DOISearch in Google Scholar

32. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003; 63:1964-76.10.1046/j.1523-1755.2003.00941.x12675893Open DOISearch in Google Scholar

33. Yang X, Wang H, Zhu Z, Deng A. Serum lipoprotein (a) concentration in patients with nephrotic syndrome and its clinical implication. J Tongji Med Univ. 1998; 18:236-8.10.1007/BF0288648110806854Open DOISearch in Google Scholar

34. Thiery J, Ivandic B, Bahlmann G, Walli AK, Seidel D. Hyperlipoprotein(a)aemia in nephrotic syndrome. Eur J Clin Invest. 1996; 26:316-21.10.1046/j.1365-2362.1996.132283.x8732490Open DOISearch in Google Scholar

35. Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther. 2007; 29:763-77.10.1016/j.clinthera.2007.05.00217697898Open DOISearch in Google Scholar

36. Araujo Junior MD. Hypertriglyceridemia represents an independent risk for coronary atherosclerosis. Arq Bras Cardiol. 1992; 59:168.Search in Google Scholar

37. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007; 176: 1113-20.10.1503/cmaj.060963Search in Google Scholar

38. Kim SB, Kang SA, Cho YJ, Park SK, Cheong HI, Lee JD, et al. Effects of low density lipoprotein on type IV collagen production by cultured rat mesangial cells. Nephron. 1994; 67:327-33.10.1159/000187988Open DOISearch in Google Scholar

39. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, et al. Urinary excretion of fatty acidbinding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004; 165:1243-55.10.1016/S0002-9440(10)63384-6Search in Google Scholar

40. Moradi H, Yuan J, Ni Z, Norris K, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic renal failure. Am J Nephrol. 2009; 30:147-54. 10.1159/000210020281381019321994Open DOISearch in Google Scholar